Replimune Group (NASDAQ:REPL) Insider Sells $65,956.80 in Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 7,248 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $65,956.80. Following the transaction, the insider owned 139,685 shares in the company, valued at $1,271,133.50. The trade was a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Replimune Group Stock Performance

Shares of Replimune Group stock traded up $0.25 during trading on Wednesday, reaching $8.99. The company’s stock had a trading volume of 1,895,576 shares, compared to its average volume of 4,388,618. The business’s 50-day moving average price is $6.56 and its 200-day moving average price is $7.39. The firm has a market cap of $705.18 million, a PE ratio of -2.60 and a beta of 0.80. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $17.00. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.26.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently modified their holdings of REPL. Russell Investments Group Ltd. raised its holdings in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares in the last quarter. US Bancorp DE grew its position in Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company’s stock valued at $45,000 after acquiring an additional 3,921 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after acquiring an additional 6,873 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter worth about $69,000. Finally, GSA Capital Partners LLP bought a new position in shares of Replimune Group in the third quarter worth about $81,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price on the stock in a report on Monday, October 20th. Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Monday, October 20th. Barclays downgraded Replimune Group from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Replimune Group in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.75.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.